Lifeline for severe bleeding disorder patients: drug access extended
NCT ID NCT06173024
First seen Sep 30, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This program offers continued access to an unlicensed medicine called recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who have already benefited from it in a previous study. Participants must have completed at least 12 months of treatment and have no other suitable options. The goal is to prevent bleeding episodes and manage the disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.